• 

  Meet Eli Lilly’s New Phase 3 Alzheimer’s Drug, Remternetug
• 

  CTAD: Lecanemab On Track to File for FDA Approval In Early 2023
• 

  Second Death Linked to Alzheimer’s Leqembi in Trial Extension
• 

  Roche Alzheimer’s Drug Fails in Trials
• 

  After 9 Years in Trials, Roche’s Crenezumab Stalls Out
• 

  More Aduhelm Drama: Packaging Could Waste Medicare Millions; Trial Tossed
• 

  Vaxxinity Wants to ‘Democratize’ Alzheimer’s Treatment With Vaccine
• 

  Biogen Abandons Aduhelm Approval Process in Europe 
• 

  Op-Ed on Aduhelm and Medicare: “Don’t Limit Our Hope”
• 

  Where’s Our Alzheimer’s Cure? Karl Herrup on What’s Taking So Long
• 

  Will Medicare Cover Aduhelm? Translating the CMS’s ‘Very Confusing’ Plan
• 

  The CMS Wants Your Input on Aduhelm Coverage—Here’s How To Comment
• 

  Why Is Everyone So Mad About Aduhelm?
• 

  Preventing Alzheimer’s Through Early Detection
• 

  Why Alzheimer’s Trials Are Recruiting Younger Patients

Previous234Next